Age-related macular degeneration progression study
Part of Eyes & vision clinical trials.
This study tracks how age-related macular degeneration (AMD) progresses over time and looks at factors that might affect your vision and quality of life. By participating, you'll help researchers understand more about AMD and what might predict better or worse outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 50 years of age or older.
- You have been diagnosed with age-related macular degeneration in at least one eye.
- You are already scheduled for regular follow-up visits as part of your standard care.
- You do not have any other serious eye problems that would affect your vision.
- You do not have any other health condition that would make long-term follow-up difficult.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks closely at how age-related macular degeneration (AMD) develops and changes over time by taking detailed eye measurements. It may help researchers better understand disease progression, especially for people who already have AMD.
This study uses eye imaging and other tests to predict if early age-related macular degeneration (AMD) will progress to a more advanced stage. It aims to help doctors identify who might need closer monitoring in the future.
This study looks at how age-related macular degeneration (AMD) affects daily activities. If you have AMD and your vision is at least 4/10, you may be able to join to help researchers understand the impact on everyday life.
This study uses artificial intelligence to track changes in the eyes of people with early or intermediate age-related macular degeneration (AMD). It aims to better understand how the disease progresses and may help doctors personalize care.
This trial uses artificial intelligence to track changes in the eyes of people with advanced age-related macular degeneration (AMD) that has caused a specific type of damage (atrophy) in the retina. The goal is to see if AI can help detect when the disease gets worse, so doctors can personalize monitoring for each patient.
This study focuses on people age 50+ with early “wasting away” changes in the macula (central retina) called atrophic lesions. It aims to better understand how these early changes progress and how they affect vision testing, which may help improve future treatments.
Hear when a new Age-Related Macular Degeneration trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.